Edition:
United States

Oculus Innovative Sciences Inc (OCLS.OQ)

OCLS.OQ on NASDAQ Stock Exchange Capital Market

4.82USD
10:55am EDT
Change (% chg)

$0.23 (+5.01%)
Prev Close
$4.59
Open
$4.62
Day's High
$4.84
Day's Low
$4.52
Volume
9,928
Avg. Vol
10,906
52-wk High
$9.65
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Oculus Innovative Sciences says Q4 revenue fell 11 pct to $3.5 mln
Thursday, 16 Jun 2016 04:05pm EDT 

Oculus Innovative Sciences Inc : Net loss for quarter ended March 31, 2016, was $2.9 million, an increase of $1.4 million . Oculus innovative sciences reports financial results for fiscal year 2016 and fourth quarter ending March 31, 2016 .Q4 revenue fell 11 percent to $3.5 million.  Full Article

Oculus Innovative Sciences, Inc says pricing of $3.4 Million Underwritten Public Offering
Friday, 18 Mar 2016 08:41am EDT 

Oculus Innovative Sciences, Inc:Says pricing of an underwritten public offering of 3,400,000 units, consisting of 3,400,000 shares of common stock.Gross proceeds to Oculus Innovative Sciences from this offering are approximately $3.4 million before deducting the underwriting discount and other estimated offering expenses.Offering is expected to close on or about March 23, 2016, subject to customary closing conditions.  Full Article

Oculus Innovative Sciences Inc announces sale of 1.65 million shares of Ruthigen stock
Tuesday, 16 Jun 2015 06:00am EDT 

Oculus Innovative Sciences Inc:Announces sale of 1.65 million shares of Ruthigen stock for $4.5 million in non-dilutive funding.Says sale is expected to close three days after the consummation of the merger between Ruthigen and Pulmatrix.Sale provides non-dilutive funding to support sales growth of dermatology products via oculus' direct sales force.Sale of its remaining 1.65 million shares of Ruthigen stock to an investor group at $2.75 per share.Says Ruthigen/Pulmatrix has until Aug. 31, 2016, to complete the sale or initiate the clinical program.  Full Article

Oculus Innovative Sciences Inc receives FDA Clearance for novel atopic dermatitis dermatology product
Monday, 8 Jun 2015 07:21pm EDT 

Oculus Innovative Sciences Inc:Says that it has received a new 510(k) clearance from U.S. Food and Drug Administration (FDA) for the company's new Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications.Produced using patented Microcyn Technology, The Alevicyn SG prescription product, under supervision of a healthcare professional, is indicated to manage and relieve burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis.Says that it may also be used to relieve the pain of first- and second-degree burns and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.  Full Article

Oculus Innovative Sciences, Inc announces sale of 350,000 shares of Ruthigen Inc
Monday, 16 Mar 2015 03:05am EDT 

Oculus Innovative Sciences, Inc:Says sale of 350,000 shares of Ruthigen Inc stock to an undisclosed investor group at $2.75 per share for non-dilutive funding of $962,500.Says additional $4.5 mln in non-dilutive funding in sale of remaining 1.65 mln Ruthigen shares upon closing of Ruthigen/Pulmatrix merger expected by no later than Aug. 2015.  Full Article

Oculus Innovative Sciences Inc announces closing of $6.3 million underwritten public offering
Monday, 26 Jan 2015 05:50pm EST 

Oculus Innovative Sciences Inc:Announced the closing of its previously announced underwritten public offering of 6,250,000 shares of common stock.And warrants to purchase an aggregate of 4,687,500 shares of common stock, at an offering price of $1.00 per share and related warrant.The warrants have an exercise price of $1.30 per share, and are exercisable for a period of five years beginning Jan. 26, 2015.The company also announced that the underwriters partially exercised the over-allotment option to purchase an additional 703,125 warrants.The underwriters have a 45-day option to purchase up to an additional 937,500 shares of common stock to cover additional over-allotments, if any.The gross proceeds to Oculus Innovative Sciences from this offering, including the underwriters' partial exercise of the over-allotment option, were about $6.3 million.  Full Article

Oculus Innovative Sciences prices public offering
Wednesday, 21 Jan 2015 09:00am EST 

Oculus Innovative Sciences Inc:Says the pricing of an underwritten public offering of 6.25 mln shares of common stock, and warrants to purchase an aggregate of 4.687,500 mln shares of common stock, at an offering price of $1.00 per share and related warrant.The warrants have an exercise price of $1.30 per share, and are exercisable for a period of five years beginning Jan. 21.The offering was upsized from 5.75 mln.The gross proceeds to from this offering are about $6.3 million before deducting the underwriting discount and other estimated offering expenses.The company has granted the underwriters a 45-day option to purchase an aggregate of up to 937,500 additional shares of common stock and/or warrants to purchase up to 703,125 shares of common stock to cover over-allotments.The offering is expected to close on or about Jan. 26.  Full Article

Oculus Innovative Sciences Inc enters into agreement to sell Ruthigen Inc shares for $5.5 mln in event of Ruthigen Merger
Monday, 12 Jan 2015 05:05am EST 

Oculus Innovative Sciences Inc:Has entered into securities purchase agreement with two current Ruthigen investors.Under which these two buyers agree to purchase all of Oculus' two mln Ruthigen (Nasdaq:RTGN) shares at $2.75 per share, or an aggregate of $5.5 mln.Says agreement expires in 60 days and is subject to Ruthigen entering into definitive agreement for merger.  Full Article

Oculus Innovative Sciences receives european CE Mark for New Microcyn based Atopic Dermatitis Hydrogel
Thursday, 30 Oct 2014 08:12am EDT 

Oculus Innovative Sciences Inc:Says issuance of a new CE Mark in Europe for Microcyn-based Pediacyn Hydrogel.Clinical results of the study includes statistically significant 50 pct reduction in the body surface area of the atopic dermatitis from baseline to week 4.Symptoms of the disease as assessed by the investigators showed that the majority of the patients at week 4 were clear or almost clear of the disease.Severity of the symptoms as indicated by the patients showed an 81 pct reduction by week 4 from the baseline.  Full Article

BRIEF-Oculus Innovative Sciences received European approval to market Sinudox

* Receives European approval to market Sinudox indicated for use in nasal irrigation